Recent News

Print
and/or
25 News Items found

Finding

Making an IMPACT: MSK’s Gene-Sequencing Test Reveals New Findings about Hereditary Cancer Risk

An analysis of germline DNA in people with advanced cancer finds that inherited mutations may be more common than expected in this group.

Kenneth Offit and Vijai Joseph

Announcement

FDA Approves First CAR T Cell Therapy for Leukemia

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

Pediatric oncologist Kevin Curran with CAR T patient Esmeralda Pineda

Announcement

FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for Advanced Blood Cancer

A new treatment option for people with acute myeloid leukemia is available, and it works in an unconventional way.

Acute myeloid leukemia cells under a microscope

In the Clinic

FDA Grants Breakthrough Therapy Designation to Omburtamab for Metastatic Neuroblastoma

A drug created at MSK called burtomab reaches an important milestone toward becoming a treatment for metastatic neuroblastoma.

MSK pediatric oncologist and neuroblastoma expert Kim Kramer

In the Clinic

The Science Behind the FDA’s Approval of an Immunotherapy for Mismatch Repair–Deficient Cancers

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

MSK medical oncologist Luis Diaz, Jr.

In the News

#ASCO17: Post-Conference Roundup of Themes and Trends

Read up on the progress being made in several key areas of cancer research, including immunotherapy, targeted therapy, precision surgery, and epigenetics.

American Society of Clinical Oncology logo

Feature

With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

Feature

The Future of Cancer Research: Five Reasons for Optimism

Discover some of the most exciting research that Memorial Sloan Kettering scientists are pursuing in the fight against cancer.

DNA molecules wrapped around histones

Decoder

What Are Exceptional Responders?

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Exceptional responders of new drugs in clinical trials.

In the Clinic

The Evolution of a Lifesaving Drug: A Scientist Reflects

Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.

Pictured: Charles Sawyers